Hypertension - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 245 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Hypertension - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Hypertension - Pipeline Review, H2 2014', provides an overview of the Hypertension's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypertension
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hypertension and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hypertension
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Hypertension Overview 11
Therapeutics Development 12
Pipeline Products for Hypertension - Overview 12
Pipeline Products for Hypertension - Comparative Analysis 13
Hypertension - Therapeutics under Development by Companies 14
Hypertension - Therapeutics under Investigation by Universities/Institutes 19
Hypertension - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Hypertension - Products under Development by Companies 25
Hypertension - Products under Investigation by Universities/Institutes 31
Hypertension - Companies Involved in Therapeutics Development 32
Sanofi 32
Eli Lilly and Company 33
GlaxoSmithKline plc 34
Daiichi Sankyo Company, Limited 35
Merck & Co., Inc. 36
Takeda Pharmaceutical Company Limited 37
BioLineRx, Ltd. 38
Novartis AG 39
Biocon Limited 40
Chong Kun Dang Pharmaceutical Corp. 41
Daewoong Pharmaceutical Co., Ltd. 42
Mitsubishi Tanabe Pharma Corporation 43
Teva Pharmaceutical Industries Limited 44
Toray Industries, Inc. 45
IntelGenx Corp. 46
Medivir AB 47
Compugen Ltd. 48
Palatin Technologies, Inc. 49
Cytokinetics, Inc. 50
Yungjin Pharm Ind. Co., Ltd. 51
Yuhan Corporation 52
Torrent Pharmaceuticals Limited 53
HanAll Biopharma Co., Ltd. 54
Ahn-Gook Pharmaceutical Co., Ltd. 55
LG Life Sciences, Ltd. 56
DiaMedica Inc. 57
CJ CheilJedang Corp. 58
Ache Laboratorios Farmaceuticos S/A 59
Cyano Biotech GmbH 60
Anacor Pharmaceuticals, Inc. 61
Innopharmax Inc. 62
QUANTUM GENOMICS Corp. 63
vasopharm GmbH 64
Omeros Corporation 65
Cellceutix Corporation 66
Esperion Therapeutics, Inc. 67
RedHill Biopharma Ltd. 68
Hanmi Pharmaceuticals, Co. Ltd. 69
TSH Biopharm Corporation Limited 70
Kadmon Corporation, LLC 71
Arromax Pharmatech, Co. Ltd. 72
AbbVie Inc. 73
Bio-inRen 74
Pharmazz, Inc. 75
Dong-A Socio Group 76
Beijing Labsolutions Pharmaceuticals Co., Ltd. 77
Hypertension - Therapeutics Assessment 78
Assessment by Monotherapy Products 78
Assessment by Combination Products 79
Assessment by Target 80
Assessment by Mechanism of Action 84
Assessment by Route of Administration 88
Assessment by Molecule Type 90
Drug Profiles 92
(sacubitril + valsartan) - Drug Profile 92
(atorvastatin calcium + losartan potassium) - Drug Profile 94
carvedilol CR - Drug Profile 95
(rosuvastatin calcium + telmisartan) - Drug Profile 97
(candesartan + amlodipine besylate) - Drug Profile 98
(rosuvastatin calcium + olmesartan medoxomil) - Drug Profile 99
carvedilol CR - Drug Profile 100
(chlorthalidone + telmisartan) - Drug Profile 101
CKD-825 - Drug Profile 102
(aspirin + lisinopril + lovastatin) - Drug Profile 103
HCP-1305 - Drug Profile 104
HCP-1302 - Drug Profile 105
(amlodipine besylate + celecoxib) - Drug Profile 106
HCP-1401 - Drug Profile 107
XY-1014KD2 - Drug Profile 108
PL-3994 - Drug Profile 109
(atorvastatin calcium + losartan potassium) - Drug Profile 111
ETC-1002 - Drug Profile 112
KD-027 - Drug Profile 114
(simvastatin Immediate Release + amlodipine maleate Delayed Release) - Drug Profile 116
LFF-269 - Drug Profile 117
(lercanidipine hydrochloride + valsartan) - Drug Profile 118
Potassium Magnesium Citrate - Drug Profile 119
dextromethorphan - Drug Profile 120
Small Molecule to Inhibit Xanthine Oxidase for Hypertension - Drug Profile 121
SP-20101 - Drug Profile 122
(amlodipine besylate + candesartan) - Drug Profile 123
QGC-001 - Drug Profile 124
(amlodipine besylate + losartan potassium) - Drug Profile 125
(simvastatin + losartan potassium) - Drug Profile 126
(simvastatin Immediate Release + amlodipine maleate Delayed Release) - Drug Profile 127
TAK-272 - Drug Profile 128
MP-157 - Drug Profile 129
AGSAV-301 - Drug Profile 130
MK-8150 - Drug Profile 131
AGSAA-010 - Drug Profile 132
CARD-024 - Drug Profile 133
(metformin + candesartan) - Drug Profile 135
(amlodipine besylate + enalapril maleate) - Drug Profile 136
CJ-30058 - Drug Profile 138
Small Molecule for Hypertension - Drug Profile 139
(amlodipine + olmesartan medoxomil) - Drug Profile 140
(amlodipine + rosuvastatin) - Drug Profile 141
(candesartan cilexetil + hydrochlorothiazide) - Drug Profile 142
KBP-5074 - Drug Profile 143
(naproxen + anti-hypertensive agent) - Drug Profile 144
CGEN-856 - Drug Profile 145
CGEN-857 - Drug Profile 146
MetPril - Drug Profile 147
KM-732 - Drug Profile 148
Small Molecule to Inhibit Renin for Hypertension - Drug Profile 149
doxazosin mesylate - Drug Profile 150
felodipine - Drug Profile 151
DM-204 - Drug Profile 152
LASSBio-785 - Drug Profile 153
GYY-4137 - Drug Profile 154
CK-2018488 - Drug Profile 156
GTP-0125 - Drug Profile 157
AGNBS-002 - Drug Profile 158
Small Molecules To Antagonize Angiotensin and Endothelin Receptor for Hypertension - Drug Profile 159
AVE-3085 - Drug Profile 160
Small Molecules to Inhibit BMP4 for Immunology and Cardiovascular Disorders - Drug Profile 161
Alanine Glyoxylate Aminotransferase-2 - Drug Profile 162
AN-3485 - Drug Profile 163
AMX-1008 - Drug Profile 164
VAS-3947 - Drug Profile 165
Drug to Inhibit 11Beta-HSD1 for Hypertension - Drug Profile 166
Peptide to Activate EpoR for Hypertension - Drug Profile 167
SOL-1 - Drug Profile 168
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Hypertension - Drug Profile 169
TRC-120038 - Drug Profile 170
Small Molecules to Inhibit Renin for Hypertension - Drug Profile 171
Elsartan - Drug Profile 172
BL-003 - Drug Profile 173
S-43126 - Drug Profile 174
TM-5441 - Drug Profile 176
siRNA to Inhibit Angiotensinogen for Hypertension - Drug Profile 178
Small Molecules to Antagonize Endothelin A Receptor for Hypertension - Drug Profile 179
Small Molecule to Inhibit Mineralocorticoid Receptor for Hypertension - Drug Profile 180
QGC-011 - Drug Profile 181
Oligonucleotide to Inhibit miRNA-22 for Hypertension - Drug Profile 182
Small Molecules for Renal and Cardiovascular Disease - Drug Profile 183
PMZ-2021 - Drug Profile 184
YHT-1808 - Drug Profile 185
Small Molecule for Hypertension and Insulin Resistance - Drug Profile 186
Small Molecule to Target GPR37L1 for Hypertension and Cardiac Hypertrophy - Drug Profile 187
Synthetic Peptide for Hypertension - Drug Profile 188
Small Molecules for Inflammatory and Metabolic Diseases - Drug Profile 189
AGNES-101 - Drug Profile 190
Tar-1 - Drug Profile 191
AZ-03 - Drug Profile 192
Small Molecule Targeting AMPD2 for Hypertension and Metabolic Disorders - Drug Profile 193
Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain - Drug Profile 194
Peptides Inhibiting ACE for Cardiovascular and Metabolic Disorders - Drug Profile 195
VU-591 - Drug Profile 196
R-190 - Drug Profile 197
Fluorophosphophloretin - Drug Profile 199
BRN-1889 - Drug Profile 200
QGC-006 - Drug Profile 201
Drugs for Hypertension - Drug Profile 202
DWJ-1351 - Drug Profile 203
metoprolol succinate - Drug Profile 204
Hypertension - Recent Pipeline Updates 205
Hypertension - Dormant Projects 215
Hypertension - Discontinued Products 226
Hypertension - Product Development Milestones 227
Featured News & Press Releases 227
Appendix 237
Methodology 237
Coverage 237
Secondary Research 237
Primary Research 237
Expert Panel Validation 237
Contact Us 238
Disclaimer 238

List of Tables
Number of Products under Development for Hypertension, H2 2014 19
Number of Products under Development for Hypertension - Comparative Analysis, H2 2014 20
Number of Products under Development by Companies, H2 2014 22
Number of Products under Development by Companies, H2 2014 (Contd..1) 23
Number of Products under Development by Companies, H2 2014 (Contd..2) 24
Number of Products under Development by Companies, H2 2014 (Contd..3) 25
Number of Products under Investigation by Universities/Institutes, H2 2014 27
Comparative Analysis by Late Stage Development, H2 2014 28
Comparative Analysis by Clinical Stage Development, H2 2014 29
Comparative Analysis by Early Stage Development, H2 2014 30
Comparative Analysis by Unknown Stage Development, H2 2014 31
Products under Development by Companies, H2 2014 32
Products under Development by Companies, H2 2014 (Contd..1) 33
Products under Development by Companies, H2 2014 (Contd..2) 34
Products under Development by Companies, H2 2014 (Contd..3) 35
Products under Development by Companies, H2 2014 (Contd..4) 36
Products under Development by Companies, H2 2014 (Contd..5) 37
Products under Investigation by Universities/Institutes, H2 2014 38
Hypertension - Pipeline by Sanofi, H2 2014 39
Hypertension - Pipeline by Eli Lilly and Company, H2 2014 40
Hypertension - Pipeline by GlaxoSmithKline plc, H2 2014 41
Hypertension - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 42
Hypertension - Pipeline by Merck & Co., Inc., H2 2014 43
Hypertension - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 44
Hypertension - Pipeline by BioLineRx, Ltd., H2 2014 45
Hypertension - Pipeline by Novartis AG, H2 2014 46
Hypertension - Pipeline by Biocon Limited, H2 2014 47
Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 48
Hypertension - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2014 49
Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 50
Hypertension - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 51
Hypertension - Pipeline by Toray Industries, Inc., H2 2014 52
Hypertension - Pipeline by IntelGenx Corp., H2 2014 53
Hypertension - Pipeline by Medivir AB, H2 2014 54
Hypertension - Pipeline by Compugen Ltd., H2 2014 55
Hypertension - Pipeline by Palatin Technologies, Inc., H2 2014 56
Hypertension - Pipeline by Cytokinetics, Inc., H2 2014 57
Hypertension - Pipeline by Yungjin Pharm Ind. Co., Ltd., H2 2014 58
Hypertension - Pipeline by Yuhan Corporation, H2 2014 59
Hypertension - Pipeline by Torrent Pharmaceuticals Limited, H2 2014 60
Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 61
Hypertension - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H2 2014 62
Hypertension - Pipeline by LG Life Sciences, Ltd., H2 2014 63
Hypertension - Pipeline by DiaMedica Inc., H2 2014 64
Hypertension - Pipeline by CJ CheilJedang Corp., H2 2014 65
Hypertension - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2014 66
Hypertension - Pipeline by Cyano Biotech GmbH, H2 2014 67
Hypertension - Pipeline by Anacor Pharmaceuticals, Inc., H2 2014 68
Hypertension - Pipeline by Innopharmax Inc., H2 2014 69
Hypertension - Pipeline by QUANTUM GENOMICS Corp., H2 2014 70
Hypertension - Pipeline by vasopharm GmbH, H2 2014 71
Hypertension - Pipeline by Omeros Corporation, H2 2014 72
Hypertension - Pipeline by Cellceutix Corporation, H2 2014 73
Hypertension - Pipeline by Esperion Therapeutics, Inc., H2 2014 74
Hypertension - Pipeline by RedHill Biopharma Ltd., H2 2014 75
Hypertension - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 76
Hypertension - Pipeline by TSH Biopharm Corporation Limited, H2 2014 77
Hypertension - Pipeline by Kadmon Corporation, LLC, H2 2014 78
Hypertension - Pipeline by Arromax Pharmatech, Co. Ltd., H2 2014 79
Hypertension - Pipeline by AbbVie Inc., H2 2014 80
Hypertension - Pipeline by Bio-inRen, H2 2014 81
Hypertension - Pipeline by Pharmazz, Inc., H2 2014 82
Hypertension - Pipeline by Dong-A Socio Group, H2 2014 83
Hypertension - Pipeline by Beijing Labsolutions Pharmaceuticals Co., Ltd., H2 2014 84
Assessment by Monotherapy Products, H2 2014 85
Assessment by Combination Products, H2 2014 86
Number of Products by Stage and Target, H2 2014 89
Number of Products by Stage and Mechanism of Action, H2 2014 93
Number of Products by Stage and Route of Administration, H2 2014 96
Number of Products by Stage and Molecule Type, H2 2014 98
Hypertension Therapeutics - Recent Pipeline Updates, H2 2014 212
Hypertension - Dormant Projects, H2 2014 222
Hypertension - Dormant Projects (Contd..1), H2 2014 223
Hypertension - Dormant Projects (Contd..2), H2 2014 224
Hypertension - Dormant Projects (Contd..3), H2 2014 225
Hypertension - Dormant Projects (Contd..4), H2 2014 226
Hypertension - Dormant Projects (Contd..5), H2 2014 227
Hypertension - Dormant Projects (Contd..6), H2 2014 228
Hypertension - Dormant Projects (Contd..7), H2 2014 229
Hypertension - Dormant Projects (Contd..8), H2 2014 230
Hypertension - Dormant Projects (Contd..9), H2 2014 231
Hypertension - Dormant Projects (Contd..10), H2 2014 232
Hypertension - Discontinued Products, H2 2014 233